DOSSIER · UPDATED 18 NOV 2025

ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.

recodetx.com ↗Claim this profile

Founded: 2015
Headcount: 135
Open roles: 1
Last raised: Debt Financing · $29M

SECTION I · THE BRIEF

Inside ReCode Therapeutics

Brief #89698Updated 18 NOV 2025MENLO PARKMEDICAL ORGANIZATIONSDEBT FINANCING

Employbl Dossier

ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.

Founded: 2015
Headcount: 135
Open roles: 1
Last raised: Debt Financing · $29M

Section II · Premium ProfileMembers only

01Engineering interview process at ReCode TherapeuticsLocked
02Tech stack & infrastructure choicesLocked
03Culture & day-to-day work styleLocked
04Why join now vs. 6 months from nowLocked
05Hiring focus & open headcount by teamLocked
06Comp philosophy and band contextLocked

Open ReCode Therapeutics brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Philip Thomas

Michael Torres

Daniel Siegwart

OPEN ROLES

Hiring at ReCode Therapeutics

Join Our Talent CommunityMenlo Park, California, United States

FUNDING

Capital raised

Total Amount Raised: $357,000,000

ReCode Therapeutics Funding Rounds

Debt Financing
$29,441,931
Sep 29, 2025
Series Unknown
$15,000,000
Nov 18, 2024
Series Unknown
$15,000,000
Nov 17, 2024
Series Unknown Investors
Cystic Fibrosis Foundation
Series B
$50,000,000
Sep 19, 2023
Series B
$50,000,000
Sep 18, 2023
Series B Investors
Bioluminescence Ventures
Matrix Capital Management
Vida Ventures
Solasta Ventures
MPM Capital
Leaps by Bayer
Sanofi-Aventis
Pfizer Venture Investments
Amgen
EcoR1 Capital
Osage University Partners II
OrbiMed Advisors
Series Unknown
$10,000,000
Jan 10, 2023
Series Unknown
$10,000,000
Jan 9, 2023
Series Unknown Investors
Cystic Fibrosis Foundation
Series B
$120,000,000
Jun 29, 2022
Series B
$120,000,000
Jun 28, 2022
Series B Investors
Leaps by Bayer
Matrix Capital Management
Amgen
Sanofi-Aventis
Pfizer Venture Investments
Series B
$80,000,000
Oct 21, 2021
Series B
$80,000,000
Oct 20, 2021
Series B Investors
EcoR1 Capital
Pfizer Venture Investments
MPM Capital
Superstring Capital
Tekla Capital Management
Osage University Partners II
NS Investment
OrbiMed Advisors
Sanofi-Aventis
Vida Ventures
Colt Ventures
Series A
$80,000,000
Mar 26, 2020
Series A
$80,000,000
Mar 25, 2020
Series A Investors
Colt Ventures
OrbiMed Advisors
Vida Ventures
MPM Capital
Osage University Partners II
Seed
$2,000,000
Feb 8, 2019
Seed
$2,000,000
Feb 7, 2019